ArticleJournal of surgical oncology2026
Does Surgical Timing After Neoadjuvant Anti-HER2 Therapy Affect Pathological Complete Response and Survival in HER2-Positive Breast Cancer? A Multicenter Retrospective Cohort Study.
Article in Journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe optimal timing of surgery after completion of neoadjuvant chemotherapy (NAC) remains uncertain, particularly for patients with HER2-positive breast cancer receiving targeted therapy.
methodsThis multicenter retrospective study included 176 patients with early or locally advanced HER2-positive breast cancer who underwent surgery following neoadjuvant chemotherapy combined with anti-HER2 therapy between 2010 and 2025. The study was conducted using a previously established multicenter real-world cohort (Birsin et al. 2025). This dataset has been used in prior analyses focusing on different endpoints; however, the current study addresses a distinct research question evaluating the impact of surgical timing after neoadjuvant therapy. Patients were categorized according to the interval between the last cycle of systemic therapy and surgery into three groups: < 4 weeks, 4-8 weeks, or > 8 weeks. The primary endpoint was pathological complete response (pCR), defined as ypT0/is ypN0. Secondary endpoints were disease-free survival (DFS) and overall survival (OS).
resultsThe median interval between completion of NAC and surgery was 8 weeks (range, 3-20 weeks). A pCR was achieved in 49% of patients. In multivariate analysis, hormone receptor negativity (OR = 2.56, p = 0.011), HER2 IHC 3+ status (OR = 0.27, p = 0.018), lower T stage (OR = 0.39, p = 0.026), and dual anti-HER2 therapy (OR = 2.47, p = 0.021) were independent predictors of pCR; however, surgical timing (< 8 weeks vs. ≥ 8 weeks; < 4 vs. 4-8 weeks; and < 4 vs. > 8 weeks) did not significantly influence pCR (p = 0.893, p = 0.171, p = 0.187). The estimated 5-year DFS rates were 87.5%, 83.5%, and 80.8%, and the OS rates were 85.2%, 82.1%, and 89.7% for the < 4-week, 4-8-week, and > 8-week groups, respectively. Neither DFS nor OS differed significantly among the groups (log-rank p = 0.828 and p = 0.778, respectively).
conclusionsIn patients with early and locally advanced HER2-positive breast cancer, the interval between completion of neoadjuvant chemotherapy combined with anti-HER2 therapy and surgery did not affect pCR, DFS, or OS. Moderate delays in surgery beyond 8 weeks did not appear to adversely affect patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.